Cutler Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cutler Group’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-400	Closed	-$11K	–	6367
2016 Q4	$11K	Buy	+400	New	+$68.2K	﹤0.01%	4067

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cutler Group's BIO Position: Q4 2021 in Review

Cutler Group sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 400 shares — an estimated $298K sold.

Cutler Group first reported a position in BIO in Q1 2016 and held it in 6 quarters. The position peaked at $493K in Q4 2016. 534 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

Cutler Group reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 400 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $298K.
Cutler Group first reported a position in Bio-Rad Laboratories Class A in Q1 2016 and held it in 6 quarters.
Cutler Group's Bio-Rad Laboratories Class A position peaked at $493K in Q4 2016.
534 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.